Table 5.
Subgroup analysis [body mass index reduction ratio < 10%, n = 206, n (%) or mean ± SD]
|
Diabetes course |
P value | |||||
| Worse | Same | Improvement | Remission | |||
| Gender | Female | 3 (8.1) | 17 (45.9) | 14 (37.8) | 3 (8.1) | 0.190 |
| Male | 21 (13.0) | 85 (52.8) | 43 (26.7) | 12 (7.5) | ||
| Age at OP (yr) | 61.9 ± 8.1 | 63.9 ± 8.0 | 63.8 ± 7.5 | 61.1 ± 9.3 | 0.976 | |
| OP type | B-Ia | 14 (13.5) | 56 (53.8) | 27 (26.0) | 7 (6.7) | 0.076 |
| B-IIa | 7 (11.3) | 33 (53.2) | 18 (29.0) | 4 (6.5) | 0.181 | |
| R-Y | 3 (9.4) | 13 (40.6) | 12 (37.5) | 4 (12.5) | ||
| Extent of gastrectomy | Subtotal (B-I, B-II) | 21 (12.7) | 89 (53.6) | 45 (27.1) | 11 (6.6) | 0.084 |
| Total (R-Y) | 3 (9.4) | 13 (40.6) | 12 (37.5) | 4 (12.5) | ||
| Duodenal bypass | Bypass – (B-I) | 14 (13.5) | 56 (53.8) | 27 (26.0) | 7 (6.7) | 0.250 |
| Bypass + (B-II, R-Y) | 10 (10.6) | 46 (48.9) | 30 (31.9) | 8 (8.5) | ||
| Pre-OP BMI (kg/m2) | 22.7 ± 2.3 | 24.3 ± 2.7 | 23.8 ± 3.0 | 22.2 ± 2.8 | 0.615 | |
| Current BMI (kg/m2) | 22.3 ± 2.2 | 23.4 ± 2.6 | 23.0 ± 3.1 | 21.3 ± 2.6 | 0.310 | |
| BMI reduction ratio1 (%) | 1.5 ± 6.6 | 3.7 ± 4.5 | 3.6 ± 5.9 | 4.2 ± 4.6 | 0.183 | |
| Pre-OP | Oral diabetic agent | 24 (13.5) | 93 (52.2) | 47 (26.4) | 14 (7.9) | 0.080 |
| diabetic | ||||||
| regimen | Insulin | 0 (0.0) | 9 (45.0) | 10 (50.0) | 1 (5.0) | |
| F/U duration (mo) | 37.7 ± 17.6 | 38.8 ± 21.7 | 30.7 ± 20.7 | 28.7 ± 14.1 | 0.022 | |
a
P = 0.674, B-I vs B-II; OP: Operation; BMI: Body mass index; F/U: Follow up; B-I : Billroth I; B-II: Billroth II; R-Y: Roux-en-Y;
1
BMI reduction ratio (%) = -[(Current BMI - Pre-OP BMI)/Pre-OP BMI] × 100.